Business
Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform
Vasa Therapeutics ("Vasa"), a clinical stage biopharmaceutical company developing transformative therapies for cardiovascular, neuromuscular, and age-related disorders, today announced an agreement with Eli Lilly and Company ("Lilly") that enables the company to utilize Lilly TuneLab, an AI-enabled drug discovery platform that provides biotech companies access to drug discovery models trained on Lilly's proprietary data.
About this update from Eli Lilly And Company
[{"type":"list","items":[{"val":[{"type":"text","content":"Vasa's CAMKII delta inhibitor, a leading discovery and development platform built on extensive crystallography data, will utilize Lilly TuneLab AI/ML predictive models to accelerate candidate selection. First-in-Human study planned for 2027. ","length":245,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":245,"olType":false},{"type":"text","content":"ENCINITAS, Calif., April 14, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical stage biopharmaceutical company developing transformative therapies for cardiovascular, neuromuscular, and age-related disorders, today announced an agreement with Eli Lilly and Company ("Lilly") that enables the company to utilize Lilly TuneLab, an AI-enabled drug discovery platform that provides biotech companies access to drug discovery models trained on Lilly's proprietary data.","length":498,"tagName":"p"},{"type":"text","content":""We are excited to utilize Lilly predictive AI/ML discovery models trained on decades of research data as a complement to our robust structural biology platform to accelerate candidate selection of our CAMKII delta asset and further expand our clinical pipeline," said Artur Plonowski, CEO and Co-Founder of Vasa. "We continue to execute on our mission to deliver transformative therapeutics to patients with limited treatment options: VS-041 is currently in a Proof-of-Mechanism trial for HFpEF, VS-214 is on track for its first-in-human trial in 2026, and we plan to initiate the Phase 1 clinical trial with our CAMKII delta inhibitor in 2027."","length":666,"tagName":"p"},{"type":"text","content":"Vasa will contribute internal experimental datasets to support the platform's continued improvement. TuneLab employs federated learning, a privacy-preserving approach that enables biopharmaceutical companies to contribute datasets and tap into Lilly's AI models without directly exposing their proprietary data or Lilly's.","length":334,"tagName":"p"},{"type":"text","content":"About Vasa Therapeutics","length":23,"tagName":"p"},{"type":"text","content":"Vasa Therapeutics is a clinical-stage biopharmaceutical company committed to delivering first-in-class innovation for cardiovascular, neuromuscular and age-related disorders. By focusing on mechanisms with strong clinical rel...